A recent study by Epic Research found that patients with diabetes who were prescribed glucagon-like peptide-1 (GLP-1) receptor agonists had a reduced likelihood of dementia diagnosis, ranging from 23% to 44%. The study included older adults with type 2 diabetes and assessed the risk of dementia within 5 years of starting a GLP-1 receptor agonist or another diabetes medication. Results showed that medications like semaglutide, exenatide, liraglutide, and dulaglutide were associated with a lower risk of dementia. The findings highlight the importance of considering cognitive health when managing diabetes in patients.
Source link
GLP-1s tied to a ‘particularly noteworthy’ decrease in likelihood of a dementia diagnosis
